Table 2 Periprocedural details in the immediate and staged in-hospital complete revascularisation groups

Symptom to PCI time (min)

180 (128–307)

203 (152–296)

0.95

Radial access (%)

50 (80.6)

27 (90.0)

0.26

Aspirin

62 (98.4)

30 (100)

0.49

Second antiplatelet agent (n, %)

63 (100)

30 (100)

1.00

GPI during PPCI (n, %)

20 (31.7)

11/29 (37.9)

0.56

Bivalirudin during PPCI (n, %)

32 (53.3)

17/27 (63.0)

0.40

Infarct related artery:

Left Anterior Descending (n, %)

20 (31.7)

11 (36.7)

0.64

Right Coronary (n, %)

24 (38.1)

19 (63.3)

0.022

Circumflex (n, %)

19 (30.2)

0 (0)

0.001

Visible thrombus (n, %)

31/62 (50.0)

26/30 (86.7)

0.001

Thrombectomy catheter (%)

39/63 (61.9)

26/30 (86.7)

0.015

Vessels with ≥75 % stenosis (n)

1.5 ± 0.6

1.6 ± 0.6

0.82

Stenosis in non-IRA lesions (%)

73.4

72.9

0.85

SYNTAX score (total)

16 (12–21.5)

18.3 (15–26)

0.021

SYNTAX score (IRA)

8 (5.5–11)

9.5 (8–16)

0.043

SYNTAX score (NIRAs)

6 (4–9)

7 (4.8–12)

0.24

Rentrop grade

0 (0–1)

1 (0–1)

0.35

Rentrop grade 2–3 pre PCI (n, %)

7/63 (11.1)

3/30 (10.0)

0.87

APPROACH area at risk (%)

26.0 ± 11.7

29.2 ± 10.8

0.21

TIMI grade pre PCI

0 (0–1)

0 (0–0)

0.47

TIMI grade post PCI

3 (3–3),

2.92 ± 0.4

3 (3–3),

2.77 ± 0.5

0.023

IRA no-reflow (n, %)

1 (1.6)

7 (23.3)

<0.001

GPI at NIRA PCI (n, %)

20 (31.7)

4 (7.7)

0.06

Bivalirudin during NIRA PCI (n, %)

32/60 (53.3)

3/28 (10.7)

<0.001

GPI or Bivalirudin at NIRA PCI (n, %)

50/60 (87.7)

7/28 (25.0)

<0.001

Total Contrast dose (ml)

295 (213–350)

390 (266–555)

0.002

Total Screening time (min)

15.5 (12–21)

21 (17–43.3)

0.001

Total Procedure length (IRA + NIRA, min)

58 (38.5–72.8)

91 (67–154.3)

<0.001

IRA PCI procedure length (min)

53 (35–70.5)

55 (37.5–81.3)

0.08

Total number of stents (n)

2.8 ± 1.1

3.4 ± 1.4

0.034

Number of stents in IRA (n)

1.3 ± 0.6

1.6 ± 0.8

0.09

Number of stents in NIRAs (n)

1.5 ± 0.8

1.8 ± 1.0

0.026